Defendant

Mallinckrodt Inc.

1 case as defendant.

Cases
1
Active
0
1 closed
Filed
2018
Top venue
D. New Jersey
1 case

Company profile

Let me research the specific case and current company details.

Let me verify the specific case details and current ownership status.

Mallinckrodt Inc. is a U.S. operating subsidiary of Mallinckrodt plc, an Irish-incorporated specialty pharmaceutical company whose business traces to 1867 in St. Louis, Missouri. It was spun out of Covidien as a separately listed company in 2013 (formerly NYSE: MNK). After two Chapter 11 filings (2020 and 2023), Mallinckrodt emerged in November 2023 with ownership transferred to its creditors and all pre-existing ordinary shares extinguished; the company states it is no longer a large-exchange listed issuer. On July 31, 2025, Mallinckrodt completed a merger with Endo, Inc., issuing cash and shares to Endo holders (legacy Mallinckrodt holders retained roughly 50.1%). A third-party aggregator (Owler) lists about 2,700 employees pre-merger.

Products / operations. Mallinckrodt runs two businesses. Specialty Brands markets Acthar Gel (repository corticotropin injection) plus its SelfJect delivery device, INOmax (inhaled nitric oxide) with the EVOLVE DS delivery system, and Terlivaz (terlipressin); Therakos photopheresis was sold to CVC Capital Partners in November 2024. Specialty Generics / "Par Health" (combining Mallinckrodt and Endo generics) makes generic drugs, sterile injectables, and active pharmaceutical ingredients, including controlled substances and acetaminophen. FY2024 net sales were about $2.0 billion; the combined company guided to roughly $3.6 billion for FY2025.

Patent-litigation posture. Mallinckrodt appears once in the tracked data — as a defendant (0 plaintiff cases, 1 defendant case). That profile is consistent with an operating company being sued, not a patent assertion entity. The matter sits in the District of New Jersey, a common Hatch-Waxman venue, not a plaintiff-friendly NPE district like the Eastern District of Texas.

Notable case. Jazz Pharmaceuticals Ireland Ltd. et al. v. Mallinckrodt Inc. (D.N.J., 2018) is a Hatch-Waxman/ANDA patent dispute. Related coverage links Jazz–Mallinckrodt litigation to sodium oxybate (Xyrem), where Mallinckrodt's Roxane unit was an ANDA filer; the specifics of this particular docket were not independently verified.